12:00 AM
 | 
Dec 11, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Patient-specific immunotherapy: Phase II data; Phase III

Genitope said that in an ongoing 25-patient Phase II study of its patient-specific immunotherapy, there were specific immune responses against the tumor-derived protein in 7...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >